Post Reply
1501-1520 of 1738
hese are some of the things Forefront Medical is doing. Its 100% own by Vicplas.
Forefront Medical Technology
Your integrated contract manufacturer for your medical device needs
Wholly-owned subsidiary of VicPlas International, a public-listed company on the Main Board
of the Singapore Stock Exchange (SGX) Serving global medical companies since 2002
Headquartered in Singapore, with additional manufacturing facilities in Changzhou and Xiamen.
FDA registered and TUV ISO 13485 accredited, state-of-the-art manufacturing facilities
Customer-centric approach with a focus on understanding and delivering the most complex
requirements Specialists in producing a wide range of medical disposable, diagnostics,
drug delivery products and electro-mechanical sub-components, including:
Laryngeal mask
Respiratory airways
Diagnostic devices
Drug delivery systems
Enteral feeding catheters
Infusion sets
Wire reinforced tubes
Optically clear components
Patient monitoring devices
Google more on Forefront Medicals for more information.
For info only.
Forefront Medical Technology
Your integrated contract manufacturer for your medical device needs
Wholly-owned subsidiary of VicPlas International, a public-listed company on the Main Board
of the Singapore Stock Exchange (SGX) Serving global medical companies since 2002
Headquartered in Singapore, with additional manufacturing facilities in Changzhou and Xiamen.
FDA registered and TUV ISO 13485 accredited, state-of-the-art manufacturing facilities
Customer-centric approach with a focus on understanding and delivering the most complex
requirements Specialists in producing a wide range of medical disposable, diagnostics,
drug delivery products and electro-mechanical sub-components, including:
Laryngeal mask
Respiratory airways
Diagnostic devices
Drug delivery systems
Enteral feeding catheters
Infusion sets
Wire reinforced tubes
Optically clear components
Patient monitoring devices
Google more on Forefront Medicals for more information.
For info only.
Just exactly what kind of medical devices do they manufacture?
MBULLISH ( Date: 06-Aug-2020 22:46) Posted:
|
haiyaa.... i believe many companies also have unpleasant history and u mentioned that was in 2010.
actually Vicplas' medical business been doing well since before covid-19 outbreak.
They don' t build up meidcal business just waiting or target virus outbreak.
Even after vaccines is ready, their medical business still profitable as usual.
During covid-19 is another boost up their profit margin same as other medical companies.
But it is true as u said focus a few hospitality counters... and avoid Airlines.
actually Vicplas' medical business been doing well since before covid-19 outbreak.
They don' t build up meidcal business just waiting or target virus outbreak.
Even after vaccines is ready, their medical business still profitable as usual.
During covid-19 is another boost up their profit margin same as other medical companies.
But it is true as u said focus a few hospitality counters... and avoid Airlines.
Kyrolliechan ( Date: 07-Aug-2020 02:18) Posted:
|
Power prediction "medtecs might return to 5 cents"! :) Glove Gang will also prob dive 95% by then.
Kyrolliechan ( Date: 07-Aug-2020 02:18) Posted:
|
Vicplas had some unpleasant history in 2010. h[t][t]ps://www.lawyerservices.in/Vicplas-Holdings-Pte-Ltd-Versus-Allfit-International-Market-Pte-Ltd-and-Others-2010-12-24
So enter at your own risk. I think all these pennies are overhyped. As the economy gets its vaccines ready in months, only manufacturing segment supporting medical distributions and accessories will benefit. Medtec and UG Healthcare will have to resume their usual business operatiions and Medtec might return to 5c very soon. Post-SARS 6 months, Medtec was trading at some 67% of its previous height and over the years, fell to just 5c. Vicplas might be the same situation too since it only support nasal swabs and respirators. People do get well and these fabs will die off. I think it is good to focus on Citydev, Genting, Sands and a few other hospitalility counters, avoid Airlines. Boeing might not last long and give another 7-8 months, airlines should be filing for chapter 11.
So enter at your own risk. I think all these pennies are overhyped. As the economy gets its vaccines ready in months, only manufacturing segment supporting medical distributions and accessories will benefit. Medtec and UG Healthcare will have to resume their usual business operatiions and Medtec might return to 5c very soon. Post-SARS 6 months, Medtec was trading at some 67% of its previous height and over the years, fell to just 5c. Vicplas might be the same situation too since it only support nasal swabs and respirators. People do get well and these fabs will die off. I think it is good to focus on Citydev, Genting, Sands and a few other hospitalility counters, avoid Airlines. Boeing might not last long and give another 7-8 months, airlines should be filing for chapter 11.
UG took one month from 34 cent to become $1
22 may to 22 June
Can the bbs of Vicplas do the same?
Waiting and wishing and watching
It will be up and down along the way as it goes higher
22 may to 22 June
Can the bbs of Vicplas do the same?
Waiting and wishing and watching
It will be up and down along the way as it goes higher
I think this is also one of the reason traders and investors all sudden flocked to Vicplas because it is a manufacturer of airway management devices and respirators
Vicplas mentioned That many companies have approached During covid and order books may have ramp up this six months plus the manufacturing of nus swab kits
The final year result and the half year result in next year March will confirm how covid has boost its revenue and profits
The pipe business is a non event as it has been stable all the years
We are all excited by the airway medical devices bullish theme play.
I believe players from UG TG medtecs Riverstone those who cashed out may caused the extreme high volume today never seen before.
May hit 40-50 very very soon
The way the sellers were taken out with such force is breathtaking today
Let?s hope to have another good day tomorrow before we go for a Long weekend
Congrats and cheers to those who invested in Vicplas.
New York, July 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Airway Management Devices Global Market Report 2020-30: Covid 19 Implications and Growth" - https://www.reportlinker.com/p05948404/?utm_source=GNW
The global airway management devices market is expected to grow from $1.40 billion in 2019 to $2.15 billion in 2020 at a compound annual growth rate (CAGR) of 53.35%. The growth is mainly due to the COVID-19 outbreak that required airway management devices to support Covid-19 patients with ease in breathing. The market is expected to stabilize and reach $2.65 billion in 2023 at a CAGR of 7.33%.
The market for the airway management devices consists of sales of airway management devices and related services. Airway management devices are used to prevent and relieve airway obstruction to ensure proper exchange of air between the patient?s lungs and atmosphere.
North America was the largest region in the airway management devices market in 2019.
In June 2018, Novo Klinik-Service GmbH, a company engaged in developing, producing and marketing innovative medical technology solutions and medical aids for intensive care, anesthesia and care sectors, announced the acquisition of Innocath for an undisclosed amount. With the acquisition, Novo Klinik-Service GmbH added ventilated patient care products of Innocath to its airway management product line. Innocath is based in Germany and its products include, tracheostomy tether, respiratory tube systems, laryngeal masks and accessories, and a range of airway management products for hospitals.
The airway management devices market covered in this report is segmented by type into infraglottic airway management devices supraglottic airway management devices resuscitators laryngoscopes other devices. It is also segmented by end-use into hospital homecare, and by application into anesthesia emergency medicine others.
The complications and failures associated with airway management devices limit the growth of airway management devices. According to BioMed Research International Journal, the concerns or complications related to the supraglottic and other airway management devices include compression of vascular structures, regurgitation, aspiration of gastric contents, trauma, and nerve injury. Therefore, higher incidences of complications associated with the airway management devices question the use of devices in the first place and likely harm the market growth.
The launch of innovative airway management devices is shaping the airway management devices market. For instance, in January 2019, Verathon, a medical device manufacturer specialized in airway management devices, announced the launch of GlideScope Core, the most flexible and comprehensive airway visualization system available for bronchoscopy, video laryngoscopy, and multimodal airway procedures. GlideScope Core was the first airway visualization system with live and simultaneous picture-in-picture imaging which offers healthcare professionals the power to see and do more. Similarly, in June 2020, Docsinnovent Ltd launched an advanced version of V-gel, which is a supraglottic airway device for cats and rabbits.
The increasing prevalence of respiratory diseases is expected to propel the demand for airway management devices market over the forecast period. Airway management devices are used for difficult emergency airway management during medical procedures. According to the publication of United for Lung Health in 2019, a forum of international respiratory societies, chronic obstructive pulmonary disease (COPD) is the third leading cause of death with an average of 384 million people suffering from COPD each year. Lung cancer was the deadliest cancer with 1.76 million deaths annually across the world. Moreover, 10 million people develop tuberculosis and 334 million people suffer from asthma every year. This scenario drives the growth of the airway management devices market.
Vicplas mentioned That many companies have approached During covid and order books may have ramp up this six months plus the manufacturing of nus swab kits
The final year result and the half year result in next year March will confirm how covid has boost its revenue and profits
The pipe business is a non event as it has been stable all the years
We are all excited by the airway medical devices bullish theme play.
I believe players from UG TG medtecs Riverstone those who cashed out may caused the extreme high volume today never seen before.
May hit 40-50 very very soon
The way the sellers were taken out with such force is breathtaking today
Let?s hope to have another good day tomorrow before we go for a Long weekend
Congrats and cheers to those who invested in Vicplas.
New York, July 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Airway Management Devices Global Market Report 2020-30: Covid 19 Implications and Growth" - https://www.reportlinker.com/p05948404/?utm_source=GNW
The global airway management devices market is expected to grow from $1.40 billion in 2019 to $2.15 billion in 2020 at a compound annual growth rate (CAGR) of 53.35%. The growth is mainly due to the COVID-19 outbreak that required airway management devices to support Covid-19 patients with ease in breathing. The market is expected to stabilize and reach $2.65 billion in 2023 at a CAGR of 7.33%.
The market for the airway management devices consists of sales of airway management devices and related services. Airway management devices are used to prevent and relieve airway obstruction to ensure proper exchange of air between the patient?s lungs and atmosphere.
North America was the largest region in the airway management devices market in 2019.
In June 2018, Novo Klinik-Service GmbH, a company engaged in developing, producing and marketing innovative medical technology solutions and medical aids for intensive care, anesthesia and care sectors, announced the acquisition of Innocath for an undisclosed amount. With the acquisition, Novo Klinik-Service GmbH added ventilated patient care products of Innocath to its airway management product line. Innocath is based in Germany and its products include, tracheostomy tether, respiratory tube systems, laryngeal masks and accessories, and a range of airway management products for hospitals.
The airway management devices market covered in this report is segmented by type into infraglottic airway management devices supraglottic airway management devices resuscitators laryngoscopes other devices. It is also segmented by end-use into hospital homecare, and by application into anesthesia emergency medicine others.
The complications and failures associated with airway management devices limit the growth of airway management devices. According to BioMed Research International Journal, the concerns or complications related to the supraglottic and other airway management devices include compression of vascular structures, regurgitation, aspiration of gastric contents, trauma, and nerve injury. Therefore, higher incidences of complications associated with the airway management devices question the use of devices in the first place and likely harm the market growth.
The launch of innovative airway management devices is shaping the airway management devices market. For instance, in January 2019, Verathon, a medical device manufacturer specialized in airway management devices, announced the launch of GlideScope Core, the most flexible and comprehensive airway visualization system available for bronchoscopy, video laryngoscopy, and multimodal airway procedures. GlideScope Core was the first airway visualization system with live and simultaneous picture-in-picture imaging which offers healthcare professionals the power to see and do more. Similarly, in June 2020, Docsinnovent Ltd launched an advanced version of V-gel, which is a supraglottic airway device for cats and rabbits.
The increasing prevalence of respiratory diseases is expected to propel the demand for airway management devices market over the forecast period. Airway management devices are used for difficult emergency airway management during medical procedures. According to the publication of United for Lung Health in 2019, a forum of international respiratory societies, chronic obstructive pulmonary disease (COPD) is the third leading cause of death with an average of 384 million people suffering from COPD each year. Lung cancer was the deadliest cancer with 1.76 million deaths annually across the world. Moreover, 10 million people develop tuberculosis and 334 million people suffer from asthma every year. This scenario drives the growth of the airway management devices market.
Singapore?s richest man?a ventilator tycoon?has grown $3.7 billion richer amid coronavirus demand boom
Shenzhen Mindray Bio-Medical Electronics Co. shares have climbed 41 fueled by a surge in demand for the life-saving devices.
Shenzhen Mindray Bio-Medical Electronics Co. shares have climbed 41 fueled by a surge in demand for the life-saving devices.
History will repeat itself .... after covid all this medical counters will drop like mad .
cherintc ( Date: 06-Aug-2020 21:21) Posted:
|
In 1999.. company with .com will surge like mad. so then we have Mediaring.com.. Horizon.com 
des_khor ( Date: 06-Aug-2020 17:49) Posted:
|
In April, forefront medical acquired arrow medical Ltd (AM). AM specialise in Cleanroom, Medical supplies and injection moulding in UK.
Also, heng swee keat also mentioned that forefront snagged 4 projects related to covid19 in July, one of its was nasal swabs production.
Medical manufacturing facilities is in sg and china
sorry. FYE July. still strange. :0
wolverine23 ( Date: 06-Aug-2020 19:29) Posted:
|
this is malaysian co? the FY reporting so strange.... FYE is Jan.... haha
Wind22i ( Date: 06-Aug-2020 19:10) Posted:
|
Side business with 60% revenue contribution with > 60% growth?
Revenue for the Group increased to $47.2 million(" M" ) for the six months ended 31 January 2020 (" 1H FY2020" ) as compared to $37.1M for the six months ended 31 January 2019 (" 1H FY2019" ), driven by higher revenue from medical devices segment which was partially offset by lower revenue from the pipes and pipe fittings segment. The revenue for the medical devices segment was $29.8M in 1H FY2020, an increase of 67.9% from 1H FY2019 due to increased orders from its customers while its segment result improved to $2.9M in 1H FY2020 from negative $0.1M in 1H FY2019. The pipes and pipe fittings segment recorded revenue of $17.3M in 1H FY2020, a decrease of 10.4% from 1H FY2019. Despite the decrease in revenue, the pipes and pipe fittings segment exercised tight cost control and its segment result improved slightly to $2.4M in 1H FY2020 from $2.3M in 1H FY2019.
Revenue for the Group increased to $47.2 million(" M" ) for the six months ended 31 January 2020 (" 1H FY2020" ) as compared to $37.1M for the six months ended 31 January 2019 (" 1H FY2019" ), driven by higher revenue from medical devices segment which was partially offset by lower revenue from the pipes and pipe fittings segment. The revenue for the medical devices segment was $29.8M in 1H FY2020, an increase of 67.9% from 1H FY2019 due to increased orders from its customers while its segment result improved to $2.9M in 1H FY2020 from negative $0.1M in 1H FY2019. The pipes and pipe fittings segment recorded revenue of $17.3M in 1H FY2020, a decrease of 10.4% from 1H FY2019. Despite the decrease in revenue, the pipes and pipe fittings segment exercised tight cost control and its segment result improved slightly to $2.4M in 1H FY2020 from $2.3M in 1H FY2019.
Depends on the flow of hot funds..
across the causeway u can see funds initially buying big on glove heavily..
and now they also targeting medical equipment and mask manufacturer..
across the causeway u can see funds initially buying big on glove heavily..
and now they also targeting medical equipment and mask manufacturer..
wolverine23 ( Date: 06-Aug-2020 18:56) Posted:
|
so this can predict $1?
Wind22i ( Date: 06-Aug-2020 18:32) Posted:
|
i read someone said next week finanical rpt out.. sure shoot up the price. i dont think they will come over here. hahaha
MBULLISH ( Date: 06-Aug-2020 16:38) Posted:
|
1.Not a sideline biz.. their medical device manufacturing segment business revenue already exceed their other business..
2.And they mention received enquiries from many/some customers to manufacture covid medical devices .
3.Plus medical stocks really bullish across the causeway.. medical manufacturer stocks are making new high everyday
2.And they mention received enquiries from many/some customers to manufacture covid medical devices .
3.Plus medical stocks really bullish across the causeway.. medical manufacturer stocks are making new high everyday
I suggest all SGX listed companies better start to do sideline Clovis related products ... your company shares will sure rockets up up to the sky !!